First study of ABBV-519 in adults with lupus or rheumatoid arthritis
Tests ABBV-519 for safety in adults with lupus or rheumatoid arthritis.
Key facts
- Who runs it
- AbbVie
- Where
- Anniston, Clearwater, Greenacres City, Houston, Jackson, Kissimmee, Miami, Orland Park, Plantation, Red Oak, Tampa, and Tustin, United StatesSee the 12 sitesAlso in 1 other country, 3 sites
- Trial code
- Registry title
- A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 30 people, planned
- Started
- 28 May 2026
- Expected to end
- Jan 2029
- Type of study
- Interventional, 5 groups
- Treatments tested
- ABBV-519
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 75 with moderate systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) who have not responded well to earlier treatments.
- Age
- 18 to 75 years
- Sex
- All sexes can join.
- Disease stage
- SLE: active disease (hSLEDAI score of 4 or more) with a positive ANA test and at least one lupus autoantibody. RA: at least 6 swollen and 6 tender joints and hs-CRP of 3 mg/L or more.
- Earlier treatment
- SLE: not enough response to at least 1 immunosuppressant used for at least 3 months. RA: at least 1 conventional DMARD and at least 1 biological or targeted DMARD of different classes did not work.
- Biomarker or test result
- B-cell count of at least 50 cells/mcL. SLE: ANA of 1:80 or higher plus anti-dsDNA, anti-Sm, anti-RNP or anti-SSA above normal. RA: rheumatoid factor or ACPA above normal.
Main reasons for not taking part
- History of infection
- Uncontrolled high blood pressure
- Active lupus affecting the nervous system or brain in the last 6 months (SLE)
- Unstable or progressive active class III or IV glomerulonephritis (SLE)
- Overlap with other autoimmune diseases such as Sjogren's disease or scleroderma
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Individuals between 18 and 75 years of age inclusive at the time of Screening
- Minimum baseline B-cell count of 50 cells/mcL
- Clinical diagnosis of SLE and fulfilling the 2019 EULAR/ACR classification criteria
- Positive ANA ≥ 1:80 and the presence of at least one of the following autoantibodies above the upper limit of normal (ULN): anti-double-stranded DNA (dsDNA), anti-Smith (Sm), anti-ribonucleoprotein (RNP), or anti-Sjogren's syndrome antigen A (SSA)
- Hybrid Systemic Lupus Erythematosus Disease Activity Index (hSLEDAI) score of ≥ 4 (excluding anti-dsDNA and C3/C4). Lupus headache or organic brain syndrome do not count towards the hSLEDAI points required for eligibility
- Participants must have an inadequate response to ≥ 1 immunosuppressant therapies, used for at least 3 months
- Clinical diagnosis of RA and fulfilling the 2010 ACR/EULAR classification criteria for RA
- Presence of rheumatoid factor (RF) or anti-citrullinated peptide antibodies (ACPA) above the ULN
- Presence of at least 6 swollen and 6 tender joints
- High-sensitivity C-reactive protein (hs-CRP) ≥ 3 mg/L
- Failed at least 1 conventional synthetic disease-modifying antirheumatic drug (DMARD) and ≥ 1 biological or targeted DMARDs of different classes
Who cannot take part
- Active neuropsychiatric SLE, or signs or symptoms of neuropsychiatric SLE within the 6 months prior to Screening (lupus headache permissible); Unstable or progressive glomerulonephritis (active class III or IV)
- Participants with a history of infection
- Participants with uncontrolled hypertension; Exclusion for SLE Participants:
- SLE overlap syndromes including, but not limited to RA, Sjogren's disease (SjD), SSc, polymyositis, dermatomyositis, or mixed connective tissue disease; Exclusion for RA Participants:; -- History of RA overlap syndromes, including but not limited to SLE, SjD, scleroderma, mixed connective tissue disorder or polymyositis
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial is currently available in United States.
Also in 1 other country, 3 sites
- Pinnacle Research GroupAnniston, United StatesTaking people
- Clinical Research Of West Florida - Phase I UnitClearwater, United StatesTaking people
- Finlay Medical Research - GreenacresGreenacres City, United StatesTaking people
- Accurate Clinical Research - HoustonHouston, United StatesTaking people
- West Tennessee Research Institute - JacksonJackson, United StatesTaking people
- Clinical Research of OsceolaKissimmee, United StatesTaking people
- Allied Biomedical Research InstituteMiami, United StatesTaking people
- Advanced Quality Medical ResearchOrland Park, United StatesTaking people
- Discovery Health Research CenterPlantation, United StatesTaking people
- Epic Medical ResearchRed Oak, United StatesTaking people
- Clinical Research Of West Florida - Tampa - North Howard AvenueTampa, United StatesTaking people
- Solace ResearchTustin, United StatesTaking people
About the trial
What the trial wants to find out
Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity.
Read full original descriptionShow less
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA.
This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally.
There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
The 5 groups in the trial
- Group 1: Dose ATreatment being tested
Participants will receive a single intravenous (IV) dose of ABBV-519
Treatment: ABBV-519
- Group 2: Dose BTreatment being tested
Participants will receive a single intravenous (IV) dose of ABBV-519
Treatment: ABBV-519
- Group 3: Dose CTreatment being tested
Participants will receive a single intravenous (IV) dose of ABBV-519
Treatment: ABBV-519
- Group 4: Dose DTreatment being tested
Participants will receive a single subcutaneous (SC) dose of ABBV-519
Treatment: ABBV-519
- Group 5: Dose ETreatment being tested
Participants will receive a single subcutaneous (SC) dose of ABBV-519
Treatment: ABBV-519
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, First-in-Human, Single Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of ABBV-519 in Subjects With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- Plain-language title
- First study of ABBV-519 in adults with lupus or rheumatoid arthritisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Criteria questions
- Built from NCT07607964, who can take part
- Record updated
- 20 October 2026